Hologic HOLX
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Hologic (HOLX) Business Model and Operations Summary
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.
Key Insights
Hologic (HOLX) Core Market Data and Business Metrics
Latest Closing Price
$61.38Market Cap
$13.92 BillionPrice-Earnings Ratio
20.95Total Outstanding Shares
232.27 Million SharesTotal Employees
7,063Dividend
No dividendIPO Date
March 1, 1990SIC Description
X-ray Apparatus & Tubes & Related Irradiation ApparatusPrimary Exchange
NASDAQHeadquarters
250 Campus Drive, Marlborough, MA, 01752
Historical Stock Splits
If you bought 1 share of HOLX before December 1, 2005, you'd have 4 shares today.
| Execution Date | Split Amount |
|---|---|
| April 3, 2008 | 2-for-1 |
| December 1, 2005 | 2-for-1 |
Cash Flow Statement
June 30, 2023 to June 29, 2024
| Metric | Value |
|---|---|
| Net Cash Flow, Continuing | $-326.80 Million |
| Exchange Gains/Losses | $900,000 |
| Net Cash Flow From Investing Activities | $-241.30 Million |
| Net Cash Flow From Financing Activities | $-1.26 Billion |
| Net Cash Flow From Operating Activities, Continuing | $1.18 Billion |
| Net Cash Flow From Investing Activities, Continuing | $-241.30 Million |
Income Statement
June 30, 2023 to June 29, 2024
| Metric | Value |
|---|---|
| Income Tax Expense/Benefit | $87.60 Million |
| Gross Profit | $2.17 Billion |
| Interest Expense, Operating | $118.30 Million |
| Operating Income/Loss | $785.10 Million |
| Basic Earnings Per Share | $2.96 |
| Basic Average Shares | $471.31 Million |
Comprehensive Income
June 30, 2023 to June 29, 2024
| Metric | Value |
|---|---|
| Other Comprehensive Income/Loss | $619 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Comprehensive Income/Loss | $709.60 Million |
| Comprehensive Income/Loss Attributable To Parent | $709.60 Million |
Balance Sheet
June 30, 2023 to June 29, 2024
| Metric | Value |
|---|---|
| Liabilities | $3.94 Billion |
| Accounts Payable | $202 Million |
| Noncurrent Liabilities | $2.94 Billion |
| Equity Attributable To Noncontrolling Interest | $0 |
| Noncurrent Assets | $4.89 Billion |
| Long-term Debt | $2.54 Billion |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||